CClinicalTrials.gg
Status unknownNCT03612830RECSINSMTsUpdated Aug 15, 2018

A Randomized Controlled Clinical Study on the Application of the Third Space in the Operation of Gastric Submucosal Tumor

An interventional study of Laparoscopy endoscopy cooperated surgery and Dan Vinchi robot endoscopy cooperated surgery in Gastric Submucosal Tumors, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2018-08-15.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Sex
All
01

Study summary

Gastric submucosal tumors (SMTs) are rare findings during routine upper endoscopy; the incidence of these lesions may be as high as 0.4%.SMTs display a wide spectrum,ranging from benign to highly malignant, with gastrointestinal stromal tumors (GISTs) being the most common type.SMTs is a gastrointestinal tumor,surgical operation is still the main method of gastric tumor treatment.The common surgical methods for resection of SMTs include laparotomy and laparoscopic surgery.In recent years, the Da Vinci robot assisted gastric resection has become a new way to treat gastric cancer. Compared with the traditional laparoscopy and laparotomy, the operation of the robot is more precise and flexible, with obvious advantages of minimally invasive and good application value and prospect.In recent years, some scholars have put forward the concept of the third space.The concept of the "third space" was initiatively proposed at the same time when new endoscopic surgery approach via natural orifice transluminal was put forward(NOTES). To be specific, with respect to the first space(lumen) and second space(peritoneal cavity),the third space refers to the intramural space.The aim of the study is to compare value (outcomes/costs) of surgery in patients with SMTs by 2 approaches:Laparoscopic and Endoscopic cooperative surgery(LECS),Robotic and Endoscopic cooperative surgery(RECS).First of all, the investigators will collect 80 cases of SMTs patients, randomly assigned for the LECS and RECS groups. Secondly, to analyzing the demographic data,basic treatment and follow-up data, including the operation time, blood loss, the number of cut edge positive, the distances of cut edge away from the tumor edge, average such confinement, the meal time, cost of treatment, tumor recurrence rate, the presence of residual stomach, upset stomach and frequency,complications and other indicators.

02

Conditions studied

  • Gastric Submucosal Tumors

Keywords

  • The Third Space
03

In context

Lead sponsor

First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 306 studies on the registry; 86 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients without contraindications gastroscope,surgery and anesthesia;
  • Gastroscope found submucosal lesions, qualitative hard;Endoscopic ultrasonography (EUS) confirmed the lesions come from the muscularis propria;
  • Tumors diameter > 2 cm;Or tumors had \< 2 cm, but the position is located in the stomach wall, after nearly cardia and it is a difficult position for gastroscope ;
  • Tumors diameter \< 5 cm, the tumors had complete, no broken feed and bleeding;
  • Not found the tumor metastasis;
  • There is no history of abdominal surgery, no severe abdominal cavity adhesion
  • Normal coagulation function;
  • There is no history of anticoagulant drugs, or who take aspirin, salvia miltiorrhiza, etc., should stop taking drugs for more than one week;
  • Patients and their families volunteered choice the surgical procedure and signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients with preoperative assessment of distant metastasis;
  • Patients with preoperative radiation and chemotherapy or hormone therapy;
  • Patients with acute obstruction, bleeding or perforation of the emergency surgery;
  • Patients with a history of abdominal trauma or abdominal surgery;
  • Patients with contraindications gastroscope,surgery and anesthesia.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    LECS

    Laparoscopic and Endoscopic cooperative surgery,LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .

    Procedure: Laparoscopy endoscopy cooperated surgery

  • Experimental
    RECS

    Robotic and Endoscopic cooperative surgery,RECS resects the tumor completely by Dan Vinchi robot with the help of the precise positioning and guidance of endoscopy .

    Procedure: Dan Vinchi robot endoscopy cooperated surgery

Interventions

  • ProcedureLaparoscopy endoscopy cooperated surgery

    LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy

  • ProcedureDan Vinchi robot endoscopy cooperated surgery

    RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy

06

What researchers measure

Primary outcomes

  1. operation time

    record in minutes,from the beginning of anesthesia to the end

    Time frame: 1 hours to 6 hours through the surgery completion

Secondary outcomes

  1. blood loss

    from the surgical record sheet

    Time frame: 1 hours to 6 hours through the surgery completion

  2. success rate

    to ensure the integrity of the tumor and obtain the negative surgical margin

    Time frame: from two days to two weeks after surgery

  3. time in bed

    the time in bed to the postoperative patient

    Time frame: from two days to two weeks after surgery

  4. time to take food

    the time to eat to the postoperative patient

    Time frame: from two days to two weeks after surgery

  5. postoperative complication rate

    including anastomotic stoma fistula,anastomotic stenosis,abdominal infection,postoperative bleeding

    Time frame: from two weeks to one year after surgery

  6. tumor recurrence rate

    periodic review the CT or MRI or endoscope

    Time frame: from one month to 2 years after surgery

  7. hospitalization expenses

    total hospitalization expenses

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
    • Jun Jun She, M.D.;Ph.D. · Contact · sjuns@sina.com · 0086-18991232713
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03612830
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Collaborators
Air Force Military Medical University, China
Responsible party
Sponsor
First posted
Aug 2, 2018
Start date
Apr 11, 2018
Primary completion
Jun 30, 2020 (estimated)
Completion
Dec 30, 2020 (estimated)
Last update
Aug 15, 2018

Study contacts

Jun Jun She, M.D; PhD
Contact
sjuns@sina.com
008618991232713
Jun Jun She
principal investigator · First Affiliated Hospital Xi'an Jiaotong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion